Elena Elkin, PhD

Associate Attending Outcomes Research Scientist

Elena Elkin

Office Phone





Harvard University

Current Research Interests

Dr. Elkin’s primary research interest is evaluating determinants of cancer screening, treatment and outcomes using population-based observational data analysis, decision analysis and patient surveys.  Her funded research agenda includes studies of the relationship between the availability of mammography resources and mammography utilization with a focus on geographic and racial disparities in access to and use of mammography; surveys of radiology facilities to assess access to screening mammography and access to low-dose chest CT for lung cancer screening; development and evaluation of a web-based decision aid for women ages 40-49 considering screening mammography; cost-effectiveness analysis of a patient-directed intervention to increase screening mammography in survivors of Hodgkin lymphoma; and studies of treatment patterns, complications, survival and costs in urologic cancers, gastrointestinal cancers and head and neck cancers in the population-based linked SEER-Medicare dataset.  Other research interests include studying the economic impact of cancer treatment on patients, their families and the health care system, and understanding and improving clinical decision-making processes from both patient and provider perspectives.

With colleagues at MSK and Weill Cornell Medical College, Dr. Elkin has developed online tools to help people make decisions about cancer screening.

Lung Screening Counselor is for current and former smokers who want to learn about lung cancer screening with low-dose chest CT and about resources to quit smoking.


  1. Elkin EB, Weinstein MC, Winer EP, Kuntz KM, Schnitt SJ, Weeks JC. HER-2 testing and trastuzumab therapy for metastatic breast cancer: A cost-effectiveness analysis. J Clin Oncol 2004; 22:854-63.

  2. Elkin EB, Hudis C, Begg CB, Schrag DS, The effect of changes in tumor size on breast cancer survival in the U.S., 1975-1999. Cancer, 2005; 104:1149-57.

  3. Elkin EB, Ishill N, Riley GF, Bach PB, Gonen M, Begg CB, Schrag D. Disenrollment from Medicare managed care among beneficiaries with and without a cancer diagnosis. J Natl Cancer Inst, 2008;100:1013-1021.

  4. Elkin EB, Ishill NM, Snow JG, Panageas KS, Bach PB, Liberman L, Wang F, Schrag D. Geographic access and the use of screening mammography. Med Care, 2010;48:349-356.

  5. Elkin EB, Bach PB. Cancer’s next frontier: addressing high and increasing costs. JAMA, 2010;303:1086-1087.

  6. Elkin EB, Marshall DA, Kulin NA, Ferrusi IL, Hassett MJ, Ladabaum U, Phillips KA, Economic evaluation of targeted cancer interventions: Critical review and recommendations. Genetics in Medicine, 2011;13:853-860.

  7. Elkin EB, Snow JG, Leoce NM, Atoria CL, Schrag D. Mammography capacity and appointment wait times: Barriers to breast cancer screening. Cancer Causes Control, 2012;23:45-50.

  8. Elkin EB, Shapiro E, Snow JG, Zauber AG, Krauskopf MS. The economic impact of a patient navigator program to increase screening colonoscopy. Cancer, 2012;118:5982-5988.

  9. Elkin EB, Atoria CL, Leoce N, Bach PB, Schrag D. Changes in the availability of screening mammography, 2000-2010. Cancer, 2013:119:3847-53.

  10. Elkin EB and Hudis CA. Parsing progress in breast cancer. J Clin Oncol, 2015;33:2837-2839.